![](https://monteverdelaw.com/wp-content/uploads/case-logo/orchard-therapeutics-plc.png)
Orchard Therapeutics plc. (Nasdaq: ORTX), relating to its proposed sale to Kyowa Kirin Co. Under the terms of the agreement, ORTX shareholders are expected to receive $16.00 and one CVR worth $1.00 in cash per American Depositary Share they own.
Orchard Therapeutics plc. (Nasdaq: ORTX), relating to its proposed sale to Kyowa Kirin Co. Under the terms of the agreement, ORTX shareholders are expected to receive $16.00 and one CVR worth $1.00 in cash per American Depositary Share they own.